Preparing for the third decade of biosimilars
Author:
- 3 August 2023
- journal article
- editorial
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 23 (8) , 651-652
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- The economics of biosimilars and challenges to biosimilar adoption in low- and middle-income countriesExpert Opinion on Biological Therapy, 2023
- Biosimilars for the next decade in Latin America: a window of opportunityExpert Opinion on Biological Therapy, 2023
- The landscape of biosimilars in Saudi Arabia: preparing for the next decadeExpert Opinion on Biological Therapy, 2023
- The status and preparation for the next decade of biosimilars in the Middle Eastern and North African regionExpert Opinion on Biological Therapy, 2023
- Preparing for the next decade of anti-VEGF biosimilars for retinal diseases: a focus on South AsiaExpert Opinion on Biological Therapy, 2023
- Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in JordanJournal of Medical Economics, 2023
- Cost-efficiency analysis of conversion to biosimilar filgrastim for supportive cancer care and resultant expanded access analysis to supportive care and early-stage HER2+ breast cancer treatment in Saudi Arabia: simulation studyJournal of Medical Economics, 2023
- Biosimilars and interchangeable biosimilars: facts every prescriber, payor, and patient should know. Insulins perspectiveExpert Opinion on Biological Therapy, 2022
- Cost Savings from Anemia Management with Biosimilar Epoetin Alfa and Increased Access to Targeted Antineoplastic Treatment: A Simulation for the EU G5 CountriesFuture Oncology, 2014